皮下泛发性T细胞淋巴瘤的遗传特征和临床特点

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancer Science Pub Date : 2024-09-17 DOI:10.1111/cas.16345
Yui Okamura, Kenichi Makishima, Yasuhito Suehara, Sakurako Suma, Yoshiaki Abe, Ryota Matsuoka, Tatsuhiro Sakamoto, Keiichiro Hattori, Yasuhisa Yokoyama, Takayasu Kato, Toru Nanmoku, Takeshi Iwasaki, Kenichi Nishiyama, Koji Kato, Yasuhide Takeuchi, Hideki Makishima, Naoya Nakamura, Shigeru Chiba, Mamiko Sakata-Yanagimoto
{"title":"皮下泛发性T细胞淋巴瘤的遗传特征和临床特点","authors":"Yui Okamura,&nbsp;Kenichi Makishima,&nbsp;Yasuhito Suehara,&nbsp;Sakurako Suma,&nbsp;Yoshiaki Abe,&nbsp;Ryota Matsuoka,&nbsp;Tatsuhiro Sakamoto,&nbsp;Keiichiro Hattori,&nbsp;Yasuhisa Yokoyama,&nbsp;Takayasu Kato,&nbsp;Toru Nanmoku,&nbsp;Takeshi Iwasaki,&nbsp;Kenichi Nishiyama,&nbsp;Koji Kato,&nbsp;Yasuhide Takeuchi,&nbsp;Hideki Makishima,&nbsp;Naoya Nakamura,&nbsp;Shigeru Chiba,&nbsp;Mamiko Sakata-Yanagimoto","doi":"10.1111/cas.16345","DOIUrl":null,"url":null,"abstract":"<p>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare peripheral T-cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five-year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in <i>HAVCR2</i>, encoding an immunomodulator. In this study, we integrated whole-exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and <i>HAVCR2</i> germline mutations in 23 of 29 patients. <i>HAVCR2</i> p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5-year median follow-up, one patient developed autoimmune-related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent <i>HAVCR2</i> germline mutations in Japanese patients, suggesting the necessity for long-term follow-up.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 11","pages":"3788-3794"},"PeriodicalIF":4.5000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16345","citationCount":"0","resultStr":"{\"title\":\"Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas\",\"authors\":\"Yui Okamura,&nbsp;Kenichi Makishima,&nbsp;Yasuhito Suehara,&nbsp;Sakurako Suma,&nbsp;Yoshiaki Abe,&nbsp;Ryota Matsuoka,&nbsp;Tatsuhiro Sakamoto,&nbsp;Keiichiro Hattori,&nbsp;Yasuhisa Yokoyama,&nbsp;Takayasu Kato,&nbsp;Toru Nanmoku,&nbsp;Takeshi Iwasaki,&nbsp;Kenichi Nishiyama,&nbsp;Koji Kato,&nbsp;Yasuhide Takeuchi,&nbsp;Hideki Makishima,&nbsp;Naoya Nakamura,&nbsp;Shigeru Chiba,&nbsp;Mamiko Sakata-Yanagimoto\",\"doi\":\"10.1111/cas.16345\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare peripheral T-cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five-year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in <i>HAVCR2</i>, encoding an immunomodulator. In this study, we integrated whole-exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and <i>HAVCR2</i> germline mutations in 23 of 29 patients. <i>HAVCR2</i> p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5-year median follow-up, one patient developed autoimmune-related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent <i>HAVCR2</i> germline mutations in Japanese patients, suggesting the necessity for long-term follow-up.</p>\",\"PeriodicalId\":9580,\"journal\":{\"name\":\"Cancer Science\",\"volume\":\"115 11\",\"pages\":\"3788-3794\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16345\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cas.16345\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16345","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

皮下泛发性T细胞淋巴瘤(SPTCL)是一种罕见的外周T细胞淋巴瘤,以皮肤病变和免疫学表现为特征。据报道,SPTCL 的五年生存率超过 80%,预后良好。最近的研究发现了编码免疫调节剂的 HAVCR2 的复发性种系变异。在这项研究中,我们整合了从 36 名 SPTCL 患者采集的 60 份样本的全外显子组测序数据,其中包括我们队列中的 6 名患者和公开数据中的 30 名患者。我们在24名患者的皮肤肿瘤中发现了138个体细胞突变,在29名患者中的23名发现了HAVCR2种系突变。在六名日本患者中,有四名发现了 HAVCR2 p.Tyr82Cys 突变。在四名患者的临床治疗过程中,所有患者都服用了环磷酰胺、羟基达诺霉素、长春新碱和泼尼松,但结果是所有四名患者都出现了不完全反应。不过,所有患者在接受了包括自体外周血干细胞移植在内的其他治疗后,病情均保持稳定。在7.5年的中位随访期间,一名患者出现了自身免疫相关疾病,一名患者出现了其他血液恶性肿瘤,最终死亡。据我们所知,这是首次报道日本患者出现复发性 HAVCR2 基因突变,这表明有必要进行长期随访。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas

Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas

Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare peripheral T-cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five-year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated whole-exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5-year median follow-up, one patient developed autoimmune-related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for long-term follow-up.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Science
Cancer Science 医学-肿瘤学
自引率
3.50%
发文量
406
审稿时长
2 months
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信